A citation-based method for searching scientific literature

Mark A Socinski, Robert M Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez-Abreu, Denis Moro-Sibilot, Christian A Thomas, Fabrice Barlesi, Gene Finley, Claudia Kelsch, Anthony Lee, Shelley Coleman, Yu Deng, Yijing Shen, Marcin Kowanetz, Ariel Lopez-Chavez, Alan Sandler, Martin Reck. N Engl J Med 2018
Times Cited: 1394



David P Carbone, Martin Reck, Luis Paz-Ares, Benjamin Creelan, Leora Horn, Martin Steins, Enriqueta Felip, Michel M van den Heuvel, Tudor-Eliade Ciuleanu, Firas Badin, Neal Ready, T Jeroen N Hiltermann, Suresh Nair, Rosalyn Juergens, Solange Peters, Elisa Minenza, John M Wrangle, Delvys Rodriguez-Abreu, Hossein Borghaei, George R Blumenschein, Liza C Villaruz, Libor Havel, Jana Krejci, Jesus Corral Jaime, Han Chang, William J Geese, Prabhu Bhagavatheeswaran, Allen C Chen, Mark A Socinski. N Engl J Med 2017
Times Cited: 1289




List of shared articles



Times cited

Advances in Small-Cell Lung Cancer (SCLC) Translational Research.
Benjamin J Drapkin, Charles M Rudin. Cold Spring Harb Perspect Med 2021
3

Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials.
Ranjan Pathak, Gilberto De Lima Lopes, Han Yu, Madan Raj Aryal, Wenyan Ji, Katherine Stemmer Frumento, Christopher J D Wallis, Zachary Klaassen, Henry S Park, Sarah B Goldberg. Cancer 2021
2


The cutting-edge progress of immune-checkpoint blockade in lung cancer.
Fei Zhou, Meng Qiao, Caicun Zhou. Cell Mol Immunol 2021
5

Nephrotoxicity in patients with solid tumors treated with anti-PD-1/PD-L1 monoclonal antibodies: a systematic review and meta-analysis.
Han Li, Jinsheng Xu, Yaling Bai, Shenglei Zhang, Meijuan Cheng, Jingjing Jin. Invest New Drugs 2021
2



Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: A systematic review and meta-analysis.
Angelo Borsarelli Carvalho Brito, Marcos Pedro Guedes Camandaroba, Vladmir Cláudio Cordeiro de Lima. Thorac Cancer 2021
1

Immunotherapy in lung cancer.
Gabriela Bravo Montenegro, Saira Farid, Stephen V Liu. J Surg Oncol 2021
2

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.
David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Ankit Bharat, Debora S Bruno, Joe Y Chang, Lucian R Chirieac, Thomas A D'Amico,[...]. J Natl Compr Canc Netw 2021
36

Outcomes of patients with non-small cell lung cancer and poor performance status treated with immune checkpoint inhibitors in the real-world setting.
Manglio Miguel Rizzo, María Virginia Bluthgen, Gonzalo Recondo, Martin Naveira, Aldo Perfetti, Florencia Rizzi, Alejandro Kuzminin, Victoria Faura, Matías Cerini, Alejandro Videla,[...]. Int J Clin Oncol 2021
1

Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Naofumi Hara, Eiki Ichihara, Daijiro Harada, Koji Inoue, Keiichi Fujiwara, Shinobu Hosokawa, Daizo Kishino, Kawai Haruyuki, Nobuaki Ochi, Naohiro Oda,[...]. J Cancer Res Clin Oncol 2021
0

PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis.
Margarita Majem, Manuel Cobo, Dolores Isla, Diego Marquez-Medina, Delvys Rodriguez-Abreu, Joaquín Casal-Rubio, Teresa Moran Bueno, Reyes Bernabé-Caro, Diego Pérez Parente, Pedro Ruiz-Gracia,[...]. J Clin Med 2021
1


Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis.
Shixue Chen, Zhibo Zhang, Xuan Zheng, Haitao Tao, Sujie Zhang, Junxun Ma, Zhefeng Liu, Jinliang Wang, Yuanyu Qian, Pengfei Cui,[...]. Front Oncol 2021
2